Combination chemotherapy in the treatment of inoperable non-small cell lung cancer
Chemotherapy is an established intervention in inoperable non-small cell lung cancer (NSCLC), yet few Irish patients receive this treatment.
To determine survival, toxicity and radiological response following chemotherapy for NSCLC at our institution.
Retrospective audit of all patients receiving chemotherapy for histologically proven, inoperable NSCLC from January 1997 to December 2000.
There were 80 treatment episodes in 77 patients, mean age 62 years. Forty-eight (60%) patients had locally advanced and 32 (40%) metastatic disease. Mitomycin, Ifosfamide, Carboplatin (MIC) and Paclitaxel/Carboplatin (PC) were the most commonly administered regimens. Median survival for locally advanced and metastatic disease was 13.9 months and 7.1 months respectively. Severe neutropenia and thrombocytopenia were each witnessed after less than 9% of cycles. Eleven (16.7%) patients had radiological response including 4 (6.1%) complete responses.
Survival for inoperable NSCLC treated with chemotherapy was encouraging and achieved at low toxicity.
KeywordsPaclitaxel Carboplatin Clin Oncol Malignant Pleural Effusion Best Supportive Care
- 1.National Cancer Registry Ireland. Cancer in Ireland, 1997. Incidence and Mortality.Lung Cancer 63–70.Google Scholar
- 2.Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in nonsmall cell lung cancer: a meta-analysis using updated data on individuals patients from 52 randomised clinical trials.BMJ 1995; 311: 899–909.Google Scholar
- 7.Roszkowski K, Pluzanska A, Krzakowski M et al. A multi-center, randomised, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or nonresectable localized non-small cell lung cancer (NSCLC).Lung Cancer 2000; 27: 145–57.CrossRefPubMedGoogle Scholar
- 17.Green MR, Kreisman H, Lickart S et al. Carboplatin in non-small cell lung cancers: the Cancer and Leukaemia Group B experience, in Bunn PA Jr, Canetta R, Ozol R et al (eds): Carboplatin (JM-8): Current Perspectives and Future Directions. Philadelphia, PA, Saunders, 1990. pp301–16.Google Scholar
- 19.Bonomi P, KyungMann K, Fairclough D et al. Comparison of survival and quality of life in advanced non-small cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group Trial.J Clin Oncol 2000; 18: 623–31.PubMedGoogle Scholar